Javascript must be enabled to continue!
Androgen Receptor-Dependent and Independent Atheroprotection by Testosterone in Male Mice
View through CrossRef
The atheroprotective effect of testosterone is thought to require aromatization of testosterone to estradiol, but no study has adequately addressed the role of the androgen receptor (AR), the major pathway for the physiological effects of testosterone. We used AR knockout (ARKO) mice on apolipoprotein E-deficient background to study the role of the AR in testosterone atheroprotection in male mice. Because ARKO mice are testosterone deficient, we sham operated or orchiectomized (Orx) the mice before puberty, and Orx mice were supplemented with placebo or a physiological testosterone dose. From 8 to 16 wk of age, the mice consumed a high-fat diet. In the aortic root, ARKO mice showed increased atherosclerotic lesion area (+80%, P < 0.05). Compared with placebo, testosterone reduced lesion area both in Orx wild-type (WT) mice (by 50%, P < 0.001) and ARKO mice (by 24%, P < 0.05). However, lesion area was larger in testosterone-supplemented ARKO compared with testosterone-supplemented WT mice (+57%, P < 0.05). In WT mice, testosterone reduced the presence of a necrotic core in the plaque (80% among placebo-treated vs. 12% among testosterone-treated mice; P < 0.05), whereas there was no significant effect in ARKO mice (P = 0.20). In conclusion, ARKO mice on apolipoprotein E-deficient background display accelerated atherosclerosis. Testosterone treatment reduced atherosclerosis in both WT and ARKO mice. However, the effect on lesion area and complexity was more pronounced in WT than in ARKO mice, and lesion area was larger in ARKO mice even after testosterone supplementation. These results are consistent with an AR-dependent as well as an AR-independent component of testosterone atheroprotection in male mice.
Title: Androgen Receptor-Dependent and Independent Atheroprotection by Testosterone in Male Mice
Description:
The atheroprotective effect of testosterone is thought to require aromatization of testosterone to estradiol, but no study has adequately addressed the role of the androgen receptor (AR), the major pathway for the physiological effects of testosterone.
We used AR knockout (ARKO) mice on apolipoprotein E-deficient background to study the role of the AR in testosterone atheroprotection in male mice.
Because ARKO mice are testosterone deficient, we sham operated or orchiectomized (Orx) the mice before puberty, and Orx mice were supplemented with placebo or a physiological testosterone dose.
From 8 to 16 wk of age, the mice consumed a high-fat diet.
In the aortic root, ARKO mice showed increased atherosclerotic lesion area (+80%, P < 0.
05).
Compared with placebo, testosterone reduced lesion area both in Orx wild-type (WT) mice (by 50%, P < 0.
001) and ARKO mice (by 24%, P < 0.
05).
However, lesion area was larger in testosterone-supplemented ARKO compared with testosterone-supplemented WT mice (+57%, P < 0.
05).
In WT mice, testosterone reduced the presence of a necrotic core in the plaque (80% among placebo-treated vs.
12% among testosterone-treated mice; P < 0.
05), whereas there was no significant effect in ARKO mice (P = 0.
20).
In conclusion, ARKO mice on apolipoprotein E-deficient background display accelerated atherosclerosis.
Testosterone treatment reduced atherosclerosis in both WT and ARKO mice.
However, the effect on lesion area and complexity was more pronounced in WT than in ARKO mice, and lesion area was larger in ARKO mice even after testosterone supplementation.
These results are consistent with an AR-dependent as well as an AR-independent component of testosterone atheroprotection in male mice.
Related Results
Abstract A6: Androgen receptor-mediated transcription is reprogrammed after hormone depletion
Abstract A6: Androgen receptor-mediated transcription is reprogrammed after hormone depletion
Abstract
Androgen receptor (AR) is a ligand-induced transcription factor, which binds to thousands of genomic loci and activates a cell-type specific gene expression...
[RETRACTED] Rhino XL Male Enhancement v1
[RETRACTED] Rhino XL Male Enhancement v1
[RETRACTED]Rhino XL Reviews, NY USA: Studies show that testosterone levels in males decrease constantly with growing age. There are also many other problems that males face due ...
Analog-Based Free Testosterone Test Results Linked to Total Testosterone Concentrations, Not Free Testosterone Concentrations
Analog-Based Free Testosterone Test Results Linked to Total Testosterone Concentrations, Not Free Testosterone Concentrations
Abstract
Background: Analog-based free testosterone test results, sex hormone binding globulin (SHBG) concentrations, and total testosterone concentrations are someh...
Episodic secretion of luteinizing hormone and androgen in male rats
Episodic secretion of luteinizing hormone and androgen in male rats
Sequential blood samples were obtained at hourly intervals from intact male rats during various phases of the light: darkness cycle. Measurement of the serum concentrations of LH a...
Metabolic clearance rate of testosterone in male epileptic patients on anti-convulsant therapy
Metabolic clearance rate of testosterone in male epileptic patients on anti-convulsant therapy
ABSTRACT
There are several reports which state that male epileptics on anti-convulsant therapy have reduced sexual activity. We and others have shown that, although total t...
Abstract B006: Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer
Abstract B006: Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer
Abstract
Background: Age-adjusted incidence and mortality rates for prostate cancer (PCa) among African American (AA) men are 1.6- and 2.4-fold greater, respectively...
Abstract PR04: Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer
Abstract PR04: Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer
Abstract
Background: Age-adjusted incidence and mortality rates for prostate cancer (PCa) among African American (AA) men are 1.6- and 2.4-fold greater, respectively...
Renal tubular (pro)renin receptor deletion does not protect against kidney injury in db/db mice
Renal tubular (pro)renin receptor deletion does not protect against kidney injury in db/db mice
Background: The (pro)renin receptor (PRR) is a multifunctional protein implicated in blood pressure regulation and kidney fibrosis. Previous studies report enhanced PRR expression ...

